Archive for August 2019
Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
Berends S.E., Steeg T.J.v., Ahsman M.J., Singh S,. Brandse J.F., D’Haens G.R.A.M., Mathôt R.A.A. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. J. Pharmacokinet. Pharmacodyn.: 5, 2019. [Link to publication]
Read MoreFavorable Pharmacokinetic Characteristics of Extended ‑ Half ‑ Life Recombinant Factor VIII BAY 94 ‑ 9027
Solms A., Iorio A., Ahsman M. J., Vis P., Shah A., Berntorp E., Garmann D. Favorable Pharmacokinetic Characteristics of Extended ‑ Half ‑ Life Recombinant Factor VIII BAY 94 ‑ 9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clin. Pharmacokinet, 2019. [Link to publication]
Read More